SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1806)10/22/2015 9:02:52 PM
From: Felix B  Read Replies (1) | Respond to of 3559
 
As George as mentioned in the past, don't see the purpose of a bispecific with this target choice, coformulation would be better. Bispecfic would be better to bring cells together or enhance selectivity.



To: Miljenko Zuanic who wrote (1806)10/27/2015 9:23:22 AM
From: DewDiligence_on_SI  Respond to of 3559
 
3Q15 ex-US Lucentis sales reported by NVS: $485M, -8% YoY in constant currency:

novartis.com (p29)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News